Skip to main content
Fig. 5 | Journal of Translational Medicine

Fig. 5

From: Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology

Fig. 5Fig. 5

Functional validation of the Nb-derived CAR-T cells anti-tumor in vivo. a Schematic diagram of in vivo experiments on tumor-bearing mice. b Dynamic growth curve of tumor volume (n = 4). Data were analyzed by two-way ANOVA. NC-T: T cells transduced with empty lentivirus vector. c Dynamic change curve of mouse weight (n = 4). d Validation of the proportion of the tumor-infiltrating T cells by flow cytometry. Data were analyzed by one-way ANOVA. e IHC of the tumor tissue sections stained with anti-human IFN-γ (left) and granzyme B (right) antibody. Scale bar, 100 µm. f IF of the tumor tissue sections stained with anti-human IFN-γ (green) and anti-human granzyme B (purple) antibodies, and the nuclei were stained with DAPI (blue). Scale bar, 100 µm. g H&E staining of major organs. Scale bar, 100 µm. h Kaplan Meier survival analysis of mice (n = 4). Data were analyzed by log-rank Mantel-Cox test. Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01

Back to article page